Trial Profile
A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 25 Dec 2023
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Omega-3-acid ethyl esters (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms ASCEND
- 08 Apr 2022 Results (n=15427) assessing effects of aspirin on dementia and cognitive functions in diabetic patients published in the European Heart Journal
- 15 Nov 2021 Results (n=15427) assessing the effect of low dose aspirin on the risk of dementia and cognitive impairment in a pre-specified secondary analysis presented at the American Heart Association Scientific Sessions 2021
- 01 Sep 2020 Results of a sub-study (N=539), assessing the association between baseline urinary TXM serious vascular events in diabetes mellitus, presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology